Innovation Pharmaceuticals Inc (IPIX)

[seek the light]

Attention IPIX management...nebulized drug!!!!

Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video
Today 9:11 AM ET (Benzinga)

Ampio Pharmaceuticals, Inc. (NYSE:AMPE),a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome ("ARDS"), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.

To view the FOX video segment in its entirety please visit the link below. Additional information about the potential suitability of the anti-inflammatory properties of Ampion being used for this clinical indication (ARDS) is included in a companion white paper summary titled, "Rationale and scientific evidence for the use of Ampion in the treatment of Acute Respiratory Distress Syndrome secondary to SARS-COV-2," provided in the link below.

https://kdvr.com/news/coronavirus/englewood-pharmaceutical-company-looking-to-treat-covid-19-patients-with-anti-inflammatory-drug/


https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf
Michael Macaluso, Ampio CEO, noted "The Company is exploring options that may enable the completion of the AP-013 study, our Phase 3 clinical trial for the treatment of severe osteoarthritis of the knee, during this COVID-19 pandemic. Simultaneously, we have directed our R&D efforts to explore the possible application of the immunomodulatory and anti-inflammatory properties of Ampion in the most severe and lethal complication of the COVID-19 infected patients: ARDS. The FDA has been very responsive, and the Company is grateful for the Agency's efforts as we work together to study the potential benefits of Ampion in this population."

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.